PatternsRadar
Sign in

INNOVACAPInnova Captab Limited

NSE
Full chart
1,141.80INR-3.60 (-0.31%)Close · 6 Oct 2026
11 Aug 2026Last results
HealthcareSector
Pharmaceuticals & BiotechnologyIndustry
₹6,534 CrMarket cap
42.4P/E (TTM)
45.1%Delivery

Filings & corporate actions

12 results filed
CSV
Next results · Q2 FY27
Expected 7 Nov 2026 – 19 Jan 2027
Estimate: filed 38–111 days after quarter end, last 3 times
Dividend
₹2.00 per share · last 30 Jan 2026
2026
  • 11 AugresultsResults · Q1 FY27 · consolidated and standalone-0.7%NSE
  • 8 JulshareholdingShareholding · 30 Jun 2026+1.5%NSE
  • 7 MayresultsResults · Q4 FY26 · consolidated and standalone+1.4%NSE
  • 9 AprshareholdingShareholding · 31 Mar 2026-0.3%NSE
  • 30 JandividendDividend · ₹2.00 per share+2.6%
  • 23 JanresultsResults · Q3 FY26 · consolidated and standalone+3.4%NSE
  • 7 JanshareholdingShareholding · 31 Dec 2025+0.1%NSE

Reaction to results · all yearsrose on day 0 in 6 of 12 CSV

QuarterFiledDay 0+5D+20DRel vol
Q1 FY2711 Aug 2026-0.7%+2.0%+16.7%14.4×
Q4 FY267 May 2026+1.4%-0.6%+0.7%1.2×
Q3 FY2623 Jan 2026+3.4%+1.9%+0.8%0.8×
Q2 FY267 Nov 2025-3.5%-4.6%-12.9%1.6×
Q1 FY267 Aug 2025+0.8%-0.4%-5.1%2.1×
Q4 FY2520 May 2025-1.4%-6.5%-5.0%1.3×
Q3 FY255 Feb 2025-5.6%-16.8%-23.9%2.1×
Q2 FY257 Nov 2024+10.4%+12.6%+26.3%13.6×
Q1 FY259 Aug 2024+1.1%+16.8%+26.6%1.1×
Q4 FY2430 May 2024+2.5%+6.0%+6.3%1.2×
Q3 FY2414 Feb 2024-2.4%-4.1%-11.8%0.4×
Q2 FY2419 Jan 2024-2.4%-4.8%-2.3%—
Average+0.3%+0.1%+1.4%

Close-to-close from the session before the filing could trade. Day 0 is the first session after it.

Growth · Q1 FY27

CSV
Revenue YoY+33.9%
Profit YoY+42.3%
Interest cost YoY+260.2%
Revenue QoQ+5.1%
Profit QoQ+15.9%
CAGR2Y3Y4Y5Y6Y7Y
Revenue+23.7%—————
Profit+20.4%—————

Key data

CSV
Open1,145.40
Day range1,115.00 – 1,159.20
52-week range622.00 – 1,353.50
From 52w high-15.6%
RSI (14)46.2
ATR (14)58.57
Volume71.9K
Avg volume (20D)1.37L
Rel volume0.53×
Volatility (1Y)35.9%
Turnover₹8.2Cr
SMA 50 / 2001,092.44 / 861.06

Delivery percentage

Latest · 6 Oct 202645.1%
20-day avg43.7%
1-year avg50.2%
Percentile (own history)29th
Range8.4–94.2%
Sessions687

Over the last 20 sessions INNOVACAP settled 43.7% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 50.2%, so recent sessions are running 6.6 points lower than usual. The latest session ranks higher than 29% of the 687 sessions on record for it.

What delivery percentage measuresScan the whole market on delivery

IndustryPharmaceuticals
PeersDIVISLABLAURUSLABSSUNPHARMAWOCKPHARMADRREDDYMOREPENLAB

Performance returns

CSV
1D1W1M3M6M1Y
Price-0.31%-10.18%+1.46%+17.94%+62.10%+35.12%

Valuation

CSV
Market cap₹6,534 Cr
P/E (TTM)42.4
EPS (TTM)26.92
Shares outstanding5.72Cr
Listed29 Dec 2023

Ownership

CSV
Promoter50.90%
Promoter Δ QoQ0.00 pp
Public49.10%
FII0.34%
DII19.92%
Pledged0.00%

Quarterly results · consolidated

CSV
Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue (₹ Cr)380.4450.3447.8470.9
YoY chg+19.5%+42.3%+42.3%+33.9%
Net profit (₹ Cr)29.742.140.344.1
YoY chg-15.2%+23.2%+36.4%+42.3%
Net margin7.8%9.4%9.0%9.4%
EPS5.187.377.057.71

Shareholding over time

CSV

By quarter

30 Jun 2026 · promoter 50.90% · public 49.10%
27 Dec 2023: promoter 50.90%31 Dec 2023: promoter 50.90%31 Mar 2024: promoter 50.90%30 Jun 2024: promoter 50.90%30 Sept 2024: promoter 50.90%31 Dec 2024: promoter 50.90%31 Mar 2025: promoter 50.90%30 Jun 2025: promoter 50.90%30 Sept 2025: promoter 50.90%31 Dec 2025: promoter 50.90%31 Mar 2026: promoter 50.90%30 Jun 2026: promoter 50.90%
2023-122026-06
  • Promoter
  • Public and others
Promoter
50.90%
Public
49.10%
Promoter change
0.00 pp
Filed
8 Jul 2026
FII
0.34%
DII
19.92%
Promoter pledged
0.00%

Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.

Financials · quarterly statement

CSV
₹ crore, as filed
 Q2 FY24Q3 FY24Q4 FY24AQ1 FY25Q2 FY25Q3 FY25Q4 FY25AQ1 FY26Q2 FY26Q3 FY26Q4 FY26ARQ1 FY27
Revenue from operations282.9302.5262.6294.3318.2316.5314.7351.5380.4450.3447.8470.9
Other income3.32.35.72.12.24.33.44.54.21.71.62.0
Total income286.3304.8268.3296.4320.4320.8318.1356.0384.6451.9449.4472.9
Total expenses256.1269.6228.8257.1273.6275.2278.8313.3345.3396.3398.7413.9
└ Finance costs8.86.80.80.10.10.22.02.95.54.04.64.4
└ Depreciation4.84.93.44.95.05.19.811.011.311.411.411.7
Profit before tax30.235.239.539.346.845.639.342.739.255.750.759.0
Tax expense7.310.110.89.811.811.49.711.79.613.510.314.9
Net profit22.925.128.729.535.034.229.631.029.742.140.344.1
EPS4.774.395.025.156.125.975.175.425.187.377.057.71
Net margin8.10%8.31%10.94%10.02%11.00%10.81%9.40%8.82%7.80%9.36%9.01%9.37%
PBT margin10.67%11.64%15.06%13.36%14.71%14.41%12.49%12.14%10.31%12.36%11.32%12.53%
Tax rate24.12%28.62%27.37%25.01%25.22%24.97%24.77%27.33%24.38%24.30%20.38%25.19%

A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 11 Aug 2026.

INNOVACAP at a glance

  • INNOVACAP closed at ₹1,141.8 on 6 Oct 2026, -0.31% on the day, +35.1% over one year, 15.6% below its 52-week high of ₹1,353.5.
  • Delivery was 45.1% of traded quantity on 6 Oct 2026, the 29th percentile of its own 687 sessions with a reading (20-session average 43.7%, 1-year average 50.2%).
  • Market capitalisation is ₹6,534 crore at a trailing P/E of 42.4 (trailing EPS ₹26.92).
  • Q1 FY27 results (consolidated, filed 11 Aug 2026): revenue ₹471 crore (+33.9% year on year), net profit ₹44 crore (+42.3%); the price moved -0.7% on the first session after.
  • Promoters held 50.90% at 30 Jun 2026, unchanged on the previous filing.
  • Q2 FY27 results are expected between 7 Nov 2026 and 19 Jan 2027, going by past filing dates — an estimate, not an announcement.

About

CSV
Macro sectorHealthcare
Basic industryPharmaceuticals
ISININE0DUT01020
SeriesEQ
Listed29 Dec 2023
History from29 Dec 2023
Sessions687
Turnover rank#860

Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.

More in Pharmaceuticals & Biotechnology

CSV

All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE